By disrupting this axis, we may impair the metabolic adaptations that enable RCC cells to survive cisplatin-induced stress-providing a rationale for combining TKT/PKM2 inhibitors with cisplatin to improve therapeutic efficacy. The gene discussed is PKM; the disease is renal cell carcinoma.